Market Exclusive

Analyst Activity – Morgan Stanley Initiates Coverage On Nabriva Therapeutics (NASDAQ:NBRV) With a Overweight

Analyst Ratings For Nabriva Therapeutics (NASDAQ:NBRV)

Today, Morgan Stanley initiated coverage on Nabriva Therapeutics (NASDAQ:NBRV) with a Overweight with a price target of $10.00.

Some recent analyst ratings include

Recent Insider Trading Activity For Nabriva Therapeutics (NASDAQ:NBRV)
Nabriva Therapeutics (NASDAQ:NBRV) has insider ownership of 2.75% and institutional ownership of 57.12%.

Recent Trading Activity for Nabriva Therapeutics (NASDAQ:NBRV)
Shares of Nabriva Therapeutics closed the previous trading session at 6.25 up +0.25 4.17% with 6.25 shares trading hands.

Exit mobile version